EGFR and non-small cell lung carcinoma: Patients with advanced EGFR-mutant NSCLC are treated with EGFR tyrosine kinase inhibitors (EGFR TKIs) such as erlotinib (1st generation), afatinib (2nd generation), and osimertinib (3rd generation).